Latest Artificial Intelligence News

Orcoda Limited has reported strong half-year FY26 results, showcasing significant growth in revenue, EBITDA, and recurring revenue as it advances its AI-powered transport ecosystem solutions.

Integral Diagnostics Limited has reported a robust half-year performance, with revenues soaring 55.6% and EBITDA nearly doubling, driven by strong patient volume growth and successful integration of Capitol Health. The company also declared a fully franked interim dividend of 3.3 cents per share.

Data#3 Limited reported a robust first half for FY26 with gross sales rising 9.1% to $1.55 billion and net profit climbing 3.7% to $23.17 million, underpinned by strong demand in infrastructure and AI-related solutions.

Navigator Global Investments reported a 17% rise in adjusted EBITDA to USD48.2 million for H1 FY26, driven by strong performance fees and asset growth, though full-year earnings face headwinds.

Praemium Limited reported a robust half-year performance with a 69.5% jump in net profit and a 9.6% rise in funds under administration, completing the OneVue platform transition and acquiring AI specialist Technotia Laboratories.

EVT Limited reported a robust first half for 2026 with revenue rising 5.4% to A$683.8 million and net profit up 21.6%, driven by strong performances in Germany, Thredbo, and Hotels. Strategic acquisitions, including Pro-invest Hotels and QT Auckland, underpin the group’s growth ambitions.

Chorus Limited has reported a strong half-year performance driven by fibre broadband growth, operational efficiencies, and a return to profitability, while launching initiatives to boost digital inclusion.

FortifAI Limited has raised $5 million through a strategic placement led by a major Australian institutional fund manager, reinforcing its balance sheet and accelerating its AI development and commercialisation plans.

QBE Insurance Group has reported its strongest financial performance in over a decade for 2025, with a 7% premium growth and a combined operating ratio improvement to 91.9%. The insurer also raised its dividend and announced a substantial share buyback, signaling confidence in sustained growth.

Alcidion has secured regulatory approval for its AI-powered clinical tool in Australia and the UK, paving the way for commercial rollout in its largest markets. This milestone strengthens its position in healthcare technology and opens new sales avenues.

NAOS Emerging Opportunities Company Limited has reported a robust half-year profit increase of 103%, alongside a fully franked interim dividend of 2.10 cents per share, reflecting strong portfolio performance and market confidence.

NAOS Small Cap Opportunities Company Limited reported a remarkable half-year profit surge and declared a steady quarterly dividend, despite portfolio returns lagging the benchmark index.